INTS logo

INTS Intensity Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.48
-0.01 (-0.60%)

Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those …

Price

No data yet.

Social Signal Score

63
5d
—
30d
63
3 mentions
—
60d
63
3 mentions
—
90d
63
3 mentions
—
news: 3

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0
Avg price target$11+343.5%
Low $7Median $11High $15
Current Consensus

Revenue

$0.00
$0.00
Dec 2020Sep 2026

Analyst Estimates

FY2025
$-7.87
$-8.10–$-7.65
3 analysts
FY2026
$-4.23
$-4.38–$-4.06
3 analysts
FY2027
$-2.56
$-3.30–$-1.80
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Lewis H. Bender
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
3.04
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-13.47
www.intensitytherapeutics.com